Casey Kristin Frye
Dec 8, 2011
New data on Bristol-Myers Squibb's investigational drug dapagliflozin
Bristol-Myers Squibb announced the results of the Phase 3 clinical trial of the investigational compound dapaglifozin, which is used to treat blood sugar levels in adults with type two diabetes, in combination with glimepiride. The study was originally 24-weeks long, but an additional 24-weeks were added in which dapagliflozin and placebo efects were studied. Compared to the placebo (also combined with glimepiride), the compound was successful in reducing the blood sugar levels. The therapy was also successful in reducing fasting plasma glucose levels, post-prandial glucose, and overall total body weight. The FDA Prescription Drug User Fee Act is dated for late January of next year.